Seeking Alpha By: Chimera Research Group Updated 12/18 /12
Article " Bullish On Amicus Therapeutics
With what we have seen from our investigations, we believe the Phase 3 trial will be positive. Amicus currently has ample cash (~$106M as of 9/30/12, EOY'12 $90M) to get into middle-2013. We suspect the AT-2220 data will come before the Phase 3 data. Not too often do we see opportunities that present themselves with such compelling conditional information before the data is known. We plan to capitalize on it.